drugset
drugset / Trial / NCT07216313

A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

NCT07216313 ↗

Phase 1 Completed 40 enrolled Sagimet Biosciences Inc.
Non-randomizedCrossoverOpen-labelTreatment

Summary

This is an open-label, 2-cohort study to evaluate the mutual DDI potential between denifanstat and resmetirom in healthy adult participants.

Timeline

Start
2025-09-30
Primary completion
2025-10-20
Completion
2025-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Denifanstat Small molecule — —
Subject Resmetirom Small molecule — —

Indications

No indication recorded.